Patients with rheumatoid arthritis (RA) face heightened risks for COVID-19 infection, hospitalization, and mortality, ...

University of Iowa researchers are recommending all patients be surveyed about their physical activity levels, after a new study underscores the link between physical activity and chronic disease.

Secukinumab is under clinical development by Novartis and currently in Phase II for Unspecified Dermatological Disorders.

Secukinumab is under clinical development by Novartis and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia.

Steqeyma is approved for adult and pediatric patients with plaque psoriasis and active psoriatic arthritis as well as adults ...